Medicine and Dentistry
Psoriasis
100%
Topical Treatment
100%
Psoriasis Vulgaris
100%
Patient Compliance
50%
Acne Vulgaris
50%
Secukinumab
50%
Biological Marker
50%
Prospective Cohort Study
50%
Biological Therapy
50%
Pyoderma gangrenosum
50%
Phototherapy
40%
Systemic Therapy
38%
Disease Process
25%
Prognostic Factor
25%
Translational Medicine
25%
Dermatology Life Quality Index
20%
Recurrent Disease
16%
Ulcer
16%
Dermatology
10%
Cigarette Smoking
10%
Psoriasis Area and Severity Index
10%
Clobetasol Propionate
8%
Retrospective Cohort Study
8%
Quality of Life
8%
Base
8%
Hazard Ratio
8%
Topical Corticosteroid
8%
Side Effect
8%
Tacrolimus
8%
Disease
8%
Dermatosis
8%
Secondary Care
8%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis Vulgaris
100%
Psoriasis
100%
Pyoderma gangrenosum
50%
Prospective Cohort Study
50%
Acne Vulgaris
50%
Secukinumab
50%
Biological Marker
50%
Calcipotriol
50%
Randomized Controlled Trial
50%
Cholecalciferol
50%
Vitamin D
50%
Disease
35%
Clinical Pharmacokinetics
25%
Placebo
22%
Recurrent Disease
20%
Betamethasone Dipropionate Plus Calcipotriol
20%
Ulcer
20%
Inflammation
15%
Interleukin 10
11%
Scanning Electron Microscopy
11%
Skin Disease
10%
Clobetasol Propionate
10%
Tacrolimus
10%
Cigarette Smoking
10%
Base
10%
Topical Corticosteroid
10%
Cohort Study
10%
Side Effect
10%
Cytokine
5%
CD3 Antigen
5%
25 Hydroxyvitamin D
5%
Immunology and Microbiology
Regulatory T Cell
100%
T Cell
66%
Immunity
60%
Cell Population
50%
Bullous Pemphigoid
50%
Scanning Electron Microscopy
50%
Interleukin 10
50%
Adalimumab
50%
CTLA-4
50%
Immunology
50%
Low Drug Dose
50%
Immune Response
35%
CD4
31%
Pemphigoid
25%
T Cell Proliferation
25%
Cytokine
25%
Metabolite
25%
CD3 Antigen
25%
Th17 Cell
12%
Cytokine Response
10%
Cytotoxic T Lymphocyte Antigen 4 Antibody
10%
Antibodies
10%
Immunosuppressive Drug
10%
Normal Human
10%
Blood Level
10%
Secretion (Process)
10%
Immune Evasion
10%
Abatacept
10%
Effector Cell
6%
